Patent 10035770 was granted and assigned to Cytokinetics on July, 2018 by the United States Patent and Trademark Office.
Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.